Immatics (IMTX) EPS (Basic) (2019 - 2026)

Immatics (IMTX) posted EPS (Basic) of -$0.34 for Q4 2025, up 31.0% sequentially from -$0.49 in Q3 2025, and down 174.35% YoY from $0.45 in Q4 2024.

Analysis

Immatics (IMTX) EPS (Basic) (2019 - 2026) Analysis & Trends

Immatics has reported EPS (Basic) for 7 years, with the latest figure at -$0.34 in Q4 2025.

Quarterly EPS (Basic) fell 174.35% year-over-year to -$0.34 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.83 (down 1397.12% YoY) and the FY2025 annual result came in at -$1.81, down 1264.64% from the prior year.
EPS (Basic) improved to -$0.34 in Q4 2025 per IMTX's latest filing, from -$0.49 in the prior quarter.
Over five years, EPS (Basic) peaked at $1.53 in Q1 2022 and troughed at -$0.66 in Q2 2025.
A 5-year average of -$0.17 and a median of -$0.32 in 2022 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2025: EPS (Basic) soared 449.28% in 2022, then plunged 109706725.86% in 2025.
Over 5 years, EPS (Basic) stood at -$0.31 in 2021, then soared by 111.02% to $0.03 in 2022, then tumbled by 1138.03% to -$0.35 in 2023, then surged by 229.8% to $0.45 in 2024, then sank by 174.35% to -$0.34 in 2025.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.34, -$0.49, and -$0.66 for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	12.62
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	7.70
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-1.96
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-3.06
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	2.12
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	1.23
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.18
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-0.06
10	Immatics	1.17 Bn	711.21 Mn	-	-0.59

Historic Data

Download Data